Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
April 11, 2024 07:00 ET
|
Eliem Therapeutics, Inc.
Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash...
Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
July 20, 2023 06:45 ET
|
Eliem Therapeutics, Inc.
SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a review of its business, including the status...
Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights
May 11, 2023 16:10 ET
|
Eliem Therapeutics, Inc.
Presented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed mechanism of action on neuronal excitability ...
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights
March 06, 2023 16:10 ET
|
Eliem Therapeutics, Inc.
Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization and pipeline reprioritization extending cash...
Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition
February 09, 2023 16:01 ET
|
Eliem Therapeutics, Inc.
Company to focus on Kv7.2/3 channel opener program and development of lead candidate, ETX-123 Pausing clinical development of ETX-155 for Major Depressive Disorder (MDD) due to challenging capital...
Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference
November 30, 2022 07:00 ET
|
Eliem Therapeutics, Inc.
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for...
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
November 14, 2022 06:10 ET
|
Eliem Therapeutics, Inc.
Positioned to initiate ETX-155 Phase 2a trial in major depressive disorder in the first quarter of 2023 with 60-milligram dose Progressing IND-enabling studies for two Kv7 pre-candidates with safety...
Eliem Therapeutics to Participate at Two Upcoming Investor Conferences
November 08, 2022 07:00 ET
|
Eliem Therapeutics, Inc.
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal...
Eliem Therapeutics Provides Update on Pipeline Progress
October 05, 2022 07:00 ET
|
Eliem Therapeutics, Inc.
Company is positioned to initiate Phase 2a trial in major depressive disorder (MDD) in the first quarter of 2023 ETX-155 demonstrating exposures in single dose 60-milligram cohorts of ongoing Phase 1...
Eliem Therapeutics Reports Second Quarter Financial and Business Highlights
August 15, 2022 06:10 ET
|
Eliem Therapeutics, Inc.
Initiated Phase 1 pharmacokinetic trial for ETX-155 with expected results in Q4 2022 Capital now expected to fund operations into 2025 SEATTLE and CAMBRIDGE, United Kingdom, Aug. 15, 2022 (GLOBE...